Andrew Hill Investment Advisors' Q2 2026 Significant Positions

The article highlights strong fundamental momentum across three biotech/pharma leaders: Eli Lilly’s diabetes and obesity franchises are driving explosive revenue growth, GE Aerospace benefits from a large installed engine base and high-margin long-term services, and Vertex remains a leader in cystic fibrosis while expanding its rare-disease business into new lucrative markets. Overall, the news reads as structurally positive for growth durability, but it provides no specific figures or catalysts that would likely move markets immediately.

Analysis

GE’s edge is not the headline revenue line, it’s the durability of the aftermarket annuity. If the installed base keeps running hot, the mix shifts toward high-margin services and free cash flow can compound even if new-unit growth normalizes; that tends to support multiple expansion versus cyclicals with less pricing power. Second-order losers are airlines and lessors with GE-heavy fleets: maintenance inflation and downtime risk quietly tax margins, and that pressure shows up with a lag over the next 2-4 quarters rather than immediately.

The biotech platform angle is more fragile than the market usually prices. A dominant franchise can fund expansion into adjacent rare diseases, but each new indication still has to clear diagnosis, reimbursement, and physician adoption — three frictions that are easy to underestimate in a bull narrative. Over 1-3 months the stock can trade on pipeline headlines; over 6-18 months the real test is whether growth broadens without a step-up in SG&A, because that determines whether the “platform” multiple deserves to persist.

Contrarian take: consensus likely treats both as quality compounding stories, but the risks are asymmetric. GE is exposed to any normalization in engine scarcity or service backlog that compresses the aftermarket spread, while the biotech name is vulnerable to the market realizing that rare-disease expansion is not a straight line from CF economics. The move looks modest enough that this is more a relative-value setup than a big directional call; the better trade is to own the asset with visible cash conversion and fade the basket that depends on future launch execution.

Key Decisions for Investors

• Long GE on pullbacks over the next 1-3 months; use it as a cash-flow quality expression, with downside falsified if services margin or backlog growth slows in the next earnings print.
• Pair trade: long GE / short JETS for a 3-6 month window to express aftermarket scarcity versus airline cost pressure; target outperformance if maintenance inflation persists and fuel remains sticky.
• Do not chase the biotech name into strength; wait for a 1-2 quarter confirmation on reimbursement/launch traction before adding risk. If forced to express the view, prefer a small long VRTX / short XBI relative-value pair.
• Set an alert on GE if engine-services growth decelerates or if management signals easing supply constraints; that would be the earliest sign the premium is peaking.